Living with ulcerative colitis: finding support and improving quality of life Despite its challenges, many individuals with ulcerative colitis can lead active, fulfilling lives.

Learn about Ulcerative Colitis symptoms, causes, diagnosis, ... The goal of treatment is to control inflammation, relieve symptoms and maintain remission (when the disease isn’t active).

Omvoh is a biologic medicine used to treat moderate to severe ulcerative colitis. ... The medicine targets interleukin (IL)-23 and contains the active ingredient mirikizumab-mrkz.

Data from the two trials – LUCENT-3 in moderately to severely active ulcerative colitis and VIVID-2 in moderately to severely active Crohn’s disease – will be presented at the American ...

AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an ...

Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.

TOPLINE: Obefazimod 50 mg once daily demonstrated efficacy in patients with moderate to severely active ulcerative colitis (UC), with 52.5% achieved clinical remission at 96 weeks of open-label ...

Similar to the ulcerative colitis trial extension findings, clinical, endoscopic, and biomarker outcomes were maintained at both doses in the Crohn's patients through week 50, but improvement was ...

The Phase 3 ABTECT trials evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 ...